Onco Actu du 18 mars 2016

	1. Biologie
Visualizing tumor blood vessels [National Cancer Institute] The team designed the microscope and tested it in melanoma patients undergoing surgery to remove a tumor. Their finding that half of the blood vessels in these tumors did not exhibit blood flow at any given time came as a surprise, Dr. Skitzki said.
	3. Prévention
Study: Genetic Tests Don’t Change Behavior [The Scientist] "The current lack of evidence is not proof that communication of genetic findings cannot influence patients. Instead, it simply suggests that communicating genetic risk will likely be very useful to a small subset of patients rather than moderately useful to everyone.”
	4.9 Dép., diag. & prono. - Sein
New MD Anderson-developed breast cancer staging system emphasizes importance of tumor biology as prognostic indicator [MD Anderson] The Neo-Bioscore staging system, published in JAMA Oncology, incorporates HER2 status, thereby allowing for more precise prognostic stratification of all breast cancer subtypes.
	5. Traitements
Watch the Hype: Cancer Treatment Still Has Far to Go [Wall Street Journal] Two decades’ achievements are modest.
	5.2 Pharma
Gilead strategy to develop cancer drugs in doubt after setbacks [STAT] His exit was reportedly unrelated to the Zydelig setback. Nonetheless, the one-two punch raises questions about the company’s ability to pursue an effective strategy for cancer treatments.
Five Lessons Big Pharma Should Learn From Valeant's Collapse [Forbes] Valeant represented a strategy of not doing R&D, and of raising prices on existing drugs. Faced with Valeant’s status as the top-performing pharma stock, many drug company CEOs have been pressured by investors to be more like Mike. Now that Valeant stock is a smoldering wreck, what lessons should the rest of the $600 billion pharmaceutical business learn?
	5.2.1 Pharma - Partenariats
Roche to Explore Combination Cancer Therapy With Kite Pharma [Bloomberg] The companies will look into whether Roche’s atezolizumab is safe and effective when used with Kite’s KTE-C19 therapy in patients with non-Hodgkin lymphoma that hasn’t responded to treatment.
	5.4 Traitements - Economie
Drug prices should reflect 'spillover effects' to family, society [STAT] Current methods for estimating the value of new drugs fail to capture the added value of better and extended life for loved ones who care for, depend on, and interact with the individual using the drug.
	6.10 Politiques
Biden Names Leader for ‘Moonshot’ Cancer Campaign [NY Times] Greg Simon, 64, who will be named executive director, took a job he may get to keep for only the last 10 months of the Obama administration. Mr. Simon, who is battling cancer himself, said he understood the urgency of the task.
	6.6 Publications
Should academics be paid for peer review? [Times Higher Education] As the number of papers needing review increases, journals are thinking of replacing a voluntary system with cash rewards.
Handful of Biologists Went Rogue and Published Directly to Internet [NY Times] The preprint movement, some #ASAPbio advocates argue, may presage the need for a greater cultural shift than scientists have yet been willing to make: evaluating one another based on the substance of their papers, not where they are published.
	6.8 Communication
Sensational Tweets on Alzheimer's & breast cancer by University of Manchester in 1 week [HealthNewsReview] The University of Manchester isn’t the only research institution taking to Twitter to flaunt questionable claims. Far from it. We can’t keep up with all of them while doing the bread-and butter-job of reviewing health news stories and releases. Fortunately, there are a growing number of eagle eyes looking for this stuff.